Author:
Loisios-Konstantinidis Ioannis,Hens Bart,Mitra Amitava,Kim Sarah,Chiann Chang,Cristofoletti Rodrigo
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Amidon GL, Lennernäs H, Shah VP, Crison JR. Theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20.
2. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62:1607–21.
3. Grimm M, Koziolek M, Kühn JP, Weitschies W. Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water. Eur J Pharm Biopharm. 2018;127:309–17.
4. U.S. Food & Drug Administration (FDA). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA — Guidance for Industry. 2013. https://www.fda.gov/files/drugs/published/Bioequivalence-Studies-With-Pharmacokinetic-Endpoints-for-Drugs-Submitted-Under-an-Abbreviated-New-Drug-Application.pdf. Accessed 03 March 2020.
5. U.S. Food & Drug Administration (FDA). Guidance for Industry SUPAC-MR: modified release solid oral dosage forms scale-up and postapproval changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. 1997. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-mr-modified-release-solid-oral-dosage-forms-scale-and-postapproval-changes-chemistry. Accessed 03 March 2020.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献